Currently, several RIPK1 inhibitors, GSK′2982772, DNL747, and DNL758, are in phase 1 or 2 clinical trials targeting inflammatory diseases such as psoriasis, ulcerative colitis, severe rheumatoid arthritis, Alzheimer’s disease, amyotrophic lateral sclerosis, and COVID-1995,96. Here, RIPK1 is linked to rheumatoid arthritis.